AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25985907
Drug: Double atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double atorvastatin dose
Trial: 25985907
Drug: Physicians' treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians' treatment recommendations
Trial: 23729226
Drug: Netupitant with
RxNorm normalized name: Netupitant
DrugBank: Netupitant (DB09048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netupitant with dexamethasone (300 mg)
Trial: 19951408
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg daily of chicken type II collagen (CCII)
Trial: 19951408
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg once a week of methotrexate (MTX)
Trial: 12846051
Drug: 7.5‐15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5‐15 mg of prednisolone (PRE) daily for one to three months followed by methotrexate (MTX) 5‐15 mg weekly if needed
Trial: 12846051
Drug: sulfasalazine (SAL),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfasalazine (SAL), supplemented with lowest possible corticosteroid dose if needed
Trial: 8601981
Drug: Erythromycin lactobionate
RxNorm normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate (200 mg in 50 ml normal saline solution intravenously)
Trial: 8601981
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 ml normal saline solution intravenously)
Trial: 1761642
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IVIG), 400 mg/kg daily for 3 days
Trial: 7346177
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) treatment, given b.i.d. (twice daily)
Trial: 7346177
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) treatment, with dose reduction
Trial: 2547950
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 to 40 mg daily)
Trial: 3002672
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 to 240 mg daily)
Trial: 3400680
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose regimen
Trial: 26482590
Drug: Radiofrequency-targeted Vertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency-targeted Vertebral Augmentation (RF-TVA)
Trial: 23012836
Drug: Diphenhydramine 1
RxNorm normalized name: diphenhydramine 18.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 1 mg x kg(‐1) intravenously
Trial: 20047897
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physostigmine and alfentanil (same doses)
Trial: 20047897
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physostigmine and alfentanil
Trial: 14759321
Drug: Ceftriaxone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (50 mg/kg, total dose < 1 g) injected once
Trial: 14759321
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg/(kg.d), tid) for 10 days
Trial: 10233203
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg racemic ibuprofen
Trial: 10233203
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg racemic ibuprofen
Trial: 8942221
Drug: Cefuroxime (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (750 mg i.v. 8H for 48 H/500 mg p.o bid)
Trial: 8942221
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (1.2 g i.v. 8 H for 48 H/750 mg p.o. tid)
Trial: 1763562
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (microspheres of size 1.0-1.2 mm)
Trial: 1763562
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (microspheres of size 1.8-2.0 mm)
Trial: 22678699
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg bid for 6 weeks
Trial: 17986636
Drug: PF-00915275 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00915275 (15 mg)
Trial: 17986636
Drug: PF-00915275 (0.3-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00915275 (0.3-15 mg)
Trial: 15664001
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin therapy (200 IU nasal spray daily during alternate months) + 400 IU Vitamin D + 1000 mg elemental calcium
Trial: 11307041
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg oral dose
Trial: 1930053
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg every 6 h)
Trial: 22014374
Drug: Low baseline
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low baseline vitamin D (<32 ng/ml) concentrations
Trial: 16905572
Drug: Oestradiol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day)
Trial: 16244006
Drug: Gabapentin, eutectic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound
Trial: 11952769
Drug: Tiagabine (TGB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB; Gabitril) 32 or 56 mg daily
Trial: 10374370
Drug: Artemether (Art)
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether (Art) - 6 mg/kg, administered every 15 days if continued exposure, with an additional dose 7-15 days after withdrawal from pilot.
Trial: 2765151
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatment methods
Trial: 1102887
Drug: Trivastal (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivastal (1 dragee daily, increasing to 3-6 dragees over 14 weeks)
Trial: 26241253
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline injection
Trial: 10967266
Drug: Antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive therapy (30 mg pamidronate IV every 3 months, n = 14)
Trial: 10967266
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy (n = 5)
Trial: 10967266
Drug: Antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive therapy (pamidronate or HRT)
Trial: 8829118
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion alone
Trial: 8829118
Drug: Furosemide infusion
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide infusion alone
Trial: 8829118
Drug: Furosemide and
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide and dopamine infusions administered concurrently
Trial: 7949627
Drug: TBARM in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBARM in ALI patients (3.05 +/‐ 0.65 nMol/ml)
Trial: 7949627
Drug: 7S collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7S collagen in ALI patients (9.06 +/‐ 5.96 ng/ml)
Trial: 23386159
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) pethidine
Trial: 20959965
Drug: Multifactorial evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial evaluation and treatment of fall risk factors
Trial: 9118614
Drug: GM-CSF 300
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF 300 U/d on days 8 and 15 post-chemotherapy for neutropenia prophylaxis
Trial: 1999086
Drug: Ciprofloxacin 300
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 300 mg i.v. every 12 hours for pneumonia
Trial: 1999086
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g i.v. every eight hours for pneumonia
Trial: 1999086
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg i.v. every 12 hours for UTI
Trial: 1999086
Drug: Ceftazidime 1
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1 g i.v. every eight hours for UTI
Trial: 31690602
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (2-year duration, 2 weekly sessions: 5 min warm-up, 20 min aerobic training, 30 min resistance training, 20 min core stability, balance and flexibility training with weighted vests)
Trial: 25746777
Drug: self‐administered mCBT‐I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐administered mCBT‐I (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks)
Trial: 25746777
Drug: no‐treatment condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no‐treatment condition (n=18)
Trial: 23403498
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/d) with hormone therapy (HT)
Trial: 23403498
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with hormone therapy (HT)
Trial: 21788220
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride 2 mg/kg per day divided 3 times daily for 6 months
Trial: 16257815
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: 15007574
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G
Trial: 9728835
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 50 or 150 microg
Trial: 795439
Drug: Dexatopic ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexatopic ointment (17 beta‐hydroxy‐4‐estren‐3‐one‐17‐decanoate)
Trial: 314399
Drug: Reference ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference ointment
Trial: 31628586
Drug: L-carnitine (500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (500-mg tablet, 2-3 times daily)
Trial: 28981445
Drug: Honey cream
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey cream
Trial: 26488737
Drug: Phenytoin cream
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin cream
Trial: 25678778
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of gemigliptin/metformin 25/500 mg
Trial: 25678778
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of gemigliptin (50 mg) and metformin XR (500 mg)
Trial: 20099536
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral treatment
Trial: 16760174
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) followed by 6‐month treatment with 3 MU thrice weekly of highly purified natural interferon‐alpha (n = 128; arm A)
Trial: 16760174
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (n = 124; arm B)
Trial: 11297592
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg moclobemide for 75 days
Trial: 11297592
Drug: Oral fluocortolone
RxNorm normalized name: fluocortolone
DrugBank: Fluocortolone (DB08971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluocortolone (tapered until day 29)
Trial: 27329280
Drug: Zolmitriptan nasal
RxNorm normalized name: Zolmitriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray (all doses)
Trial: 15755389
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of flu vaccine (FV)
Trial: 15755389
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of flu vaccine (FV)
Trial: 1851340
Drug: Zileuton (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (800 mg, single oral dose)
Trial: 6996072
Drug: Diflunisal (0.5‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (0.5‐1 g/day)
Trial: 6996072
Drug: Aspirin (2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2‐4 g/day)
Trial: 26062186
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion treatment applied twice a week for 8 weeks.
Trial: 17439907
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (GB), 120 mg twice a day for 12 weeks
Trial: 2766313
Drug: Habitual oral
RxNorm normalized name: Habitrol Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habitual oral hygiene
Trial: 939970
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy totaling 4000 to 4500 rads in 4 to 5 weeks (Group 1)
Trial: 939970
Drug: 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) 130 mg/sq m orally every 6 weeks (Group 2)
Trial: 939970
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus CCNU (Group 3)
Trial: 16133077
Drug: 0.35% povidone-iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35% povidone-iodine solution followed by normal saline solution
Trial: 1361775
Drug: Dextrose only
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose only (usual treatment) for 4 weeks
Trial: 27356701
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (listening to classical songs through headphones)
Trial: 16003041
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular volume (mL/m)
Trial: 16003041
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume (mL/m)
Trial: 16003041
Drug: Stroke volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke volume (mL/m)
Trial: 8398323
Drug: Salvage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatment after local recurrence
Trial: 3962762
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units calcium heparin subcutaneously 8-hourly for two weeks
Trial: 31613046
Drug: Preprocedural anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprocedural anticoagulation (63% of patients, primarily intravenous unfractionated heparin)
Trial: 30214185
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI (glycopyrrolate/formoterol fumarate, 18/9.6 μg, twice daily)
Trial: 27619983
Drug: ipragliflozin (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipragliflozin (50-100 mg once daily)
Trial: 27619983
Drug: control (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (continuation of conventional therapy)
Trial: 24862215
Drug: Rilpivirine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine long-acting (RPV-LA) 300 mg
Trial: 24862215
Drug: Rilpivirine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine long-acting (RPV-LA) 600 mg
Trial: 24862215
Drug: Rilpivirine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine long-acting (RPV-LA) 1,200 mg
Trial: 12628949
Drug: Ramipril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (10 mg daily)
Trial: 9061125
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (400 mL daily during hospital stay and 200 mL daily for 6 months at home)
Trial: 9061125
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual care without supplements)
Trial: 30786835
Drug: JVS-100 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JVS-100 8 mg
Trial: 30786835
Drug: JVS-100 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JVS-100 16 mg
Trial: 29966016
Drug: SRLS 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRLS 100 mg
Trial: 29966016
Drug: SRLS 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRLS 200 mg
Trial: 29966016
Drug: SRLS 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRLS 400 mg
Trial: 29966016
Drug: PLGA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLGA 100 mg
Trial: 17433902
Drug: Oral formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulations of female hormone replacement
Trial: 15827780
Drug: Cytoreduction and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (35 mg/m2) at 40-41 degrees C for 90 minutes
Trial: 12221381
Drug: 60% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% lidocaine gel
Trial: 10547222
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 40 mg orally 15 minutes before thrombolysis, followed by 20 mg every 8 hours
Trial: 31766063
Drug: Improvement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvement of 25(OH)D levels from <75 nmol/l to ≥75 nmol/l (median: 40.2 nmol/l to 83.2 nmol/l)
Trial: 31766063
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with consistently <75 nmol/l 25(OH)D levels
Trial: 21311765
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid with low prevalence of antiplatelet therapy (60% on average)
Trial: 21311765
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid with high prevalence of antiplatelet therapy (91% on average)
Trial: 17284097
Drug: Remifentanil (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (bolus of 1.0 microg/kg, continuous infusion from 0.25 to 0.05 microg/kg/min)
Trial: 17284097
Drug: Alfentanil (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (bolus of 10 microg/kg, continuous infusion from 2.0 to 0.5 microg/kg/min)
Trial: 12039615
Drug: Psychotropic analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic analgesic nitrous oxide (PAN)
Trial: 1827098
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg 12-hourly for 14 days
Trial: 1827098
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate 500 mg 6-hourly for 14 days
Trial: 7178675
Drug: Neo‐Biphyllin Mikroklysma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo‐Biphyllin Mikroklysma (400 mg Theophylline, 600 mg Diprophylline, 600 mg Proxyphylline)
Trial: 29943872
Drug: 6-week knee
RxNorm normalized name: BOS TAURUS KNEE JOINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week knee extensor training program (twice-weekly, five sets of 12 stretches, 3 seconds per stretch)